NEW YORK, July 24 (Praxis Press) Th2 cytokines are strongly implicated in the immunopathology of asthma. Tamaoki and colleagues evaluated the steroid-sparing effect of suplatast tosilate, a selective Th2 cytokine inhibitor, relative to placebo in patients with steroid-dependent asthma. When steroid doses were halved, patients in the suplatast tosilate group had less deterioration of pulmonary function, asthma symptoms, and reliance on beta2-agonists for relief. These benefits were achieved with
The Scientist Staff
NEW YORK, July 24 (Praxis Press) Th2 cytokines are strongly implicated in the immunopathology of asthma. Tamaoki and colleagues evaluated the steroid-sparing effect of suplatast tosilate, a selective Th2 cytokine inhibitor, relative to placebo in patients with steroid-dependent asthma. When steroid doses were halved, patients in the suplatast tosilate group had less deterioration of pulmonary function, asthma symptoms, and reliance on beta2-agonists for relief. These benefits were achieved with few side effects. Suplatast tosilate may allow a reduction of steroid dose in patients with steroid-dependent asthma.
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!